Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDASimplywall·8 hours agoTEVA+3.17%
Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)Simplywall·2 days ago, 06:43 PMTEVA+3.17%
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drugbenzinga_article·Aug 20 at 08:30 AMAUPH+1.09%TEVA+3.17%
Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036PUBT·Aug 19 at 03:05 PMAUPH+1.09%TEVA+3.17%
Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28PUBT·Aug 19 at 03:01 PMTEVA+3.17%
FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority reviewPUBT·Aug 19 at 07:31 AMTEVA+3.17%
Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?Simplywall·Aug 15 at 02:34 PMTEVA+3.17%
Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High After Analyst UpgradeMarket Beat·Aug 13 at 09:40 AMTEVA+3.17%
Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00Market Beat·Aug 12 at 07:48 AMTEVA+3.17%
Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVAMarket Beat·Aug 12 at 03:56 AMTEVA+3.17%
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth StrategyUnusual Whales·Aug 11 at 07:03 AMTEVA+3.17%
Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVAMarket Beat·Aug 8 at 02:28 AMTEVA+3.17%
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays OpenSimplywall·Aug 7 at 10:48 AMTEVA+3.17%
